Cytomedix acquires stem cell company Aldagen

02/8/2012 | MedCityNews.com

Cytomedix purchased Aldagen for $16 million in stock, expanding the former's pipeline of regenerative therapies. The acquisition "provides Cytomedix with a novel, patent-protected cell selection technology that fits well with our existing commercial products and strengthens our long-range growth profile," Cytomedix CEO Martin Rosendale said.

View Full Article in:

MedCityNews.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI